Heart failure in diabetes: From an increased risk to a treatment target
Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there ha...
Saved in:
| Main Author: | Eberhard Standl |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2018-11-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/9846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01) -
Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01) -
Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01) -
Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01) -
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)